The test, developed by EDP Biotech, will initially be introduced to the 30 member states of the European Economic Area.
ColoMarker has been clinically tested in the United States. It has demonstrated 97 percent sensitivity, 86 percent specificity for colorectal cancer and a 48 percent detection rate of adenomatous polyps.
More articles on gastroenterology:
Are current endoscopy cleaning protocols enough?
Hudson Valley Hospital Center adds 2 gastroenterologists
HCV drug Sovaldi sales on the decline
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.